Walvax Biotechnology Co., Ltd.
Walvax Biotechnology is a Kunming-based vaccine maker listed in Shenzhen (SZSE: 300142). Its 13-valent pneumococcal conjugate vaccine (PCV13-TT) is approved in China, and in October 2026 it began a technology transfer of the vaccine to VBC in Egypt.
| Headquarters | Kunming, China |
|---|---|
| Listing | SZSE:300142 |
| Lead asset / stage | PCV13-TT Approved — China |
| Latest event | Walvax announced launch of PCV13-TT technology transfer with VBC in Egypt. |